SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 40.47 |
| Enterprise Value ($M) | 30.10 |
| Book Value ($M) | 52.14 |
| Book Value / Share | 3.80 |
| Price / Book | 0.79 |
| NCAV ($M) | 2.85 |
| NCAV / Share | 0.21 |
| Price / NCAV | 14.18 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.26 |
| Return on Assets (ROA) | -0.18 |
| Return on Equity (ROE) | -0.21 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 6.06 |
| Current Ratio | 6.06 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 11.94 |
| Assets | 61.22 |
| Liabilities | 9.09 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Hirschman Orin | 5.10 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,345 | 29,908 | 4.50 | |
| 4,917 | 23,461 | 20.96 | |
| 10,634 | 51,796 | 20.53 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| GNLX – Genelux Corporation | GNPX – Genprex, Inc. |
| GOVX – GeoVax Labs, Inc. | GTBP – GT Biopharma, Inc. |
| GYRE – Gyre Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io